Ramipril

Generic Name
Ramipril
Brand Names
Altace, Altace HCT
Drug Type
Small Molecule
Chemical Formula
C23H32N2O5
CAS Number
87333-19-5
Unique Ingredient Identifier
L35JN3I7SJ
Background

Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure...

Indication

For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high ...

Associated Conditions
Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event
Associated Therapies
-
Clinical Trials
Related News

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

Phase 3
Completed
Conditions
Hypertension
First Posted Date
2006-01-25
Last Posted Date
2017-12-28
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1354
Registration Number
NCT00281593
Locations
🇺🇸

1236.1.573 Boehringer Ingelheim Investigational Site, Long Beach, California, United States

🇺🇸

1236.1.560 Boehringer Ingelheim Investigational Site, Encinitas, California, United States

🇺🇸

1236.1.523 Boehringer Ingelheim Investigational Site, Buena Park, California, United States

and more 116 locations

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

Phase 4
Completed
Conditions
Hypertension
First Posted Date
2006-01-11
Last Posted Date
2023-12-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
812
Registration Number
NCT00274599
Locations
🇺🇸

Spartanburg Medical Research, Spartanburg, South Carolina, United States

🇺🇸

Harold B. Betton, M.D., Little Rock, Arkansas, United States

🇺🇸

GFI Pharmaceuticals, Evansville, Indiana, United States

and more 7 locations

Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM

Phase 4
Completed
Conditions
Hypertension
First Posted Date
2006-01-11
Last Posted Date
2013-11-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
801
Registration Number
NCT00274612
Locations
🇦🇹

Rehabilitationszentrum für Herz- und Kreislauferkrankungen, Bad Tatzmannsdorf, Austria

🇦🇹

Landeskrankenhaus Graz West, Graz, Austria

🇦🇹

Univ.-Klinik für Innere Medizin III, Wien, Austria

and more 16 locations

Ramipril in Rheumatoid Arthritis

Phase 2
Completed
Conditions
Arthritis, Rheumatoid
First Posted Date
2006-01-09
Last Posted Date
2008-07-22
Lead Sponsor
University of Zurich
Target Recruit Count
13
Registration Number
NCT00273533

FOCUS:Focus On Coronary Unstable Syndromes

Phase 3
Completed
Conditions
Myocardial Ischemia
First Posted Date
2005-12-22
Last Posted Date
2011-01-11
Lead Sponsor
Sanofi
Registration Number
NCT00268619

Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
Hypertension
First Posted Date
2005-10-18
Last Posted Date
2013-11-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
96
Registration Number
NCT00240422
Locations
🇩🇪

Boehringer Ingelheim Investigational Site, Nürnberg, Germany

🇩🇪

Friedrich-Alexander-Universität, Erlangen, Germany

🇩🇪

Universität Erlangen-Nürnberg, Nürnberg, Germany

and more 1 locations

Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes

Phase 3
Terminated
Conditions
Hypertension
Type 2 Diabetes
Albuminuria
First Posted Date
2005-09-21
Last Posted Date
2007-11-08
Lead Sponsor
Institut de Recherches Cliniques de Montreal
Target Recruit Count
50
Registration Number
NCT00208221
Locations
🇨🇦

Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada

The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease

Phase 4
Completed
Conditions
Peripheral Arterial Disease
First Posted Date
2005-09-15
Last Posted Date
2009-01-29
Lead Sponsor
Baker Heart Research Institute
Target Recruit Count
40
Registration Number
NCT00168467
Locations
🇦🇺

Alfred Hospital, Melbourne, Victoria, Australia

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Phase 4
Completed
Conditions
Cardiovascular Diseases
First Posted Date
2005-09-12
Last Posted Date
2014-05-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
31546
Registration Number
NCT00153101
Locations
🇺🇸

502.373.0247 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States

🇺🇸

502.373.0177 Boehringer Ingelheim Investigational Site, Tuscon, Arizona, United States

🇦🇺

502.373.0529 Launceston General Hospital, Launceston, Tasmania, Australia

and more 729 locations

Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)

First Posted Date
2005-09-01
Last Posted Date
2013-03-22
Lead Sponsor
Vanderbilt University
Target Recruit Count
455
Registration Number
NCT00141778
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy